Elli Lilly is now launching the newly approved Effient (prasugrel). The company set nearly a 100% price premium for Effient over Plavix ($5.40 per Effient pill versus $3 per Plavix pill), despite the black box warnings on Effient. This comes at a time when healthcare reform talks are at a peak and drug price negotiations by Medicare Part D are “on the table” as a way to fund the reform bill.
The Healthcare Channel interviewed William O’Neill, Executive Dean for Clinical Affairs at the University of Miami School of Medicine. Dr. O’Neill is quite upset at the price for Effient and discusses how it is now common for his medical center to treat patients that cannot afford the price for oral medications.
No comments:
Post a Comment